2026-06-14T02:29:51Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/179992024-09-21T18:11:41Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Colhoun, Helen M
author
Leiter, Lawrence A
author
Müller-Wieland, Dirk
author
Cariou, Bertrand
author
Ray, Kausik K
author
Tinahones, Francisco J
author
Domenger, Catherine
author
Letierce, Alexia
author
Israel, Marc
author
Samuel, Rita
author
Del Prato, Stefano
2024-02-12T19:45:20Z
2024-02-12T19:45:20Z
2020-02-08
10.1186/s12933-020-0991-1
1475-2840
Cardiovascular diabetology
http://hdl.handle.net/10668/15076
32035487
http://hdl.handle.net/20.500.12105/17999
Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and apolipoprotein B (ApoB) are the preferred therapeutic targets for mixed dyslipidemia. Alirocumab is a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9) that effectively reduces low-density lipoprotein cholesterol (LDL-C), non-HDL-C, ApoB, and lipoprotein(a) (Lp[a]), and is well-tolerated in individuals with T2DM. The previously reported open-label ODYSSEY DM-DYSLIPIDEMIA trial data demonstrated the effects of alirocumab on individuals with non-HDL-C ≥ 100 mg/dL and TGs ≥ 150 and Alirocumab significantly reduced non-HDL-C [LS mean difference (standard error (SE)), - 35.0% (3.9)], ApoB [LS mean difference (SE), - 34.7% (3.6)], LDL-C [LS mean difference (SE), - 47.3% (5.2)], LDL particle number [LS mean difference (SE), - 40.8% (4.1)], and Lp(a) [LS mean difference (SE), - 29.9% (5.4)] versus usual care from baseline to Week 24 (all P Alirocumab is an effective therapeutic option for individuals with T2DM, TGs ≥ 200 mg/dL, and HDL-C
eng
Alirocumab
DM-DYSLIPIDEMIA
Diabetes mellitus
HDL-C
Non-HDL-C
ODYSSEY
PCSK9
Triglycerides
Type 2 diabetes
Usual care
Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
research article